94 results about "Therapeutic group" patented technology

The present invention relates to systems and devices for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In particular, the present invention relates to systems and devices for the delivery of energy employing a center fed dipole component. In certain embodiments, methods are provided for treating a tissue region (e.g., a tumor) through application of energy with the systems and devices of the present invention.

The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.

The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and / or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a Burkholderia antigen) that generate an effective immune response (e.g., against a bacterial species of the genus Burkholderia) in a subject administered the immunogenic composition. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.

A Self-contained, portable therapy and game case assembly having sliding and opening sections and compartments and portions of the therapy assembly which can be utilized together or separately is disclosed. The therapy assembly is provided for use with various symbolized or illustrated inlay and sliding sheets, for testing and prompting selected skills and associative thinking. The invention is provided as a coupled and portably transportable first and second subassemblies. The first subassembly is provided from outside or outboard to inside or inboard, when in assembled position, with a first sliding feature which recieves a sliding first transparent sliding member; a symbolized inlay sheet; a feature for securing a stationary member which receives an erasable board member; a dividing storage area secured adjacent and inboard or inside of the erasable board member; and a second sliding feature which receives a second transparent sliding member so that it can be positioned inside the divided storage area as a cover. The second subassembly is provided, outboard to inboard with a sliding feature which recieves one or more peg-board sheets; a first feature for stationary securement receiving a pivotable and symbolized multiple-door unit; second stationary feature receiving a transparent sheet; slot feature receiving a symbolized sheet; and a third stationary feature receiving an inboard wall panel.

The present invention relates to systems and devices for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In particular, the present invention relates to systems and devices for the delivery of energy employing a center fed dipole component. In certain embodiments, methods are provided for treating a tissue region (e.g., a tumor) through application of energy with the systems and devices of the present invention.

Methods for treating a vascular disease by delivering therapeutic compositions with enhanced endothelium targeting are disclosed.

A focused-ultrasound or other procedure for treating a target within a tissue region can be planned iteratively by creating a treatment plan specifying a treatment location pattern and stimuli applied thereto, simulating the treatment, computationally predicting an effect of the simulated treatment, comparing the predicted effect against one or more treatment constraints (such as efficacy and / or safety thresholds), and, if a constraint is violated, repeating the simulation for an adjusted treatment plan.

As described below, the present invention features methods for reprogramming somatic cells and related therapeutic compositions and methods.

The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Systems and methods of localizing or delivery cells, biologics and / or drugs to a specific target area to treat pelvic health disorders are provided. A treatment composition including cells, biologics and / or drugs are associated with magnetic particulates, and the positioning of these materials is facilitated through use of a magnetic field-generating device that is configured to be placed on or into a pelvic anatomical structure. Certain embodiments directed to the treatment of ED in male patients can include a cell based therapy system.

The invention provides methods and systems for assessing the efficacy of a pharmaceutical which is putatively disease modifying of a cognitive disorder, for use in the treatment or prophylaxis of that cognitive disorder, the method comprising the steps of: (1) stratifying a subject group into at least 2 sub-groups according to a baseline indicator of likely disease progression, (2) treating members of each subject group with the pharmaceutical for a treatment time frame, (3) deriving psychometric and optionally physiological outcome measures for each treated patient group, (4) comparing the outcomes at (3) with a comparator arm of said sub-groups which is optionally a placebo or minimal efficacy comparator arm, (5) using the comparison in (4) to derive an efficacy measure for the pharmaceutical. The methods and systems of the invention address problems such as low rate of decline over the treatment time-frame of patients who have mild-disease severity at baseline and biased withdrawal, particularly in the placebo / comparator treatment arm.

The invention discloses a single-chain antibody of human source anti-alexin C3d molecules. A light chain and a heavy chain of the antibody have a unique CDR region; excellent antigen binding activityis realized; the affinity constant reaches 1.22*10<-7> mol / L. Biological distribution experiments prove that the anti-C3d single-chain antibody provided by the invention can be highly gathered in thearthritis positions after entering a mouse model with rheumatoid arthritis; the arthritis serious degree of the three ScFv treatment groups is obviously lower than that of a PBS group; the healing degree has the obvious dose dependency relationship; the result shows that the excellent anti-adhesion / anti-inflammatory targeted inhibition effects are achieved. In the treatment process on MRL / lpr mice with lupus erythematosus, the anti-C3d single-chain antibody provided by the invention can obviously improve the survival rate of the mice; the symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis and crescent / necrosis and the like in the treatment group are obviously relieved. The result shows that the anti C3d single-chain antibody provided by the invention has excellent application prospects in the preparation of medicine for treating autoimmune diseases.

Systems, methods, and apparatuses for treating a tissue site are described. In some embodiments, the system may include a dressing, a negative-pressure source, and a communication device. The communication device may be coupled to the negative-pressure source and configured to transmit operational data of the negative pressure source to a remote location for monitoring usage of the system.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures.

A focused-ultrasound or other procedure for treating a target within a tissue region can be planned iteratively by creating a treatment plan specifying a treatment location pattern and stimuli applied thereto, simulating the treatment, computationally predicting an effect of the simulated treatment, comparing the predicted effect against one or more treatment constraints (such as efficacy and / or safety thresholds), and, if a constraint is violated, repeating the simulation for an adjusted treatment plan.

Disclosed are linear discrete PEG constructs, which can be created and produced in a precise and reproducible way. Key to being able to do these things, where x in the discrete PEGx can vary from about 2 to about 64, is that the processes used to make each linear portion is controlled to give essentially one oligomer / one compound. Having a variable length linear discrete PEG construct that is (a) primarily an linear discrete PEG construct with diagnostic or therapeutic groups attached along a chain of attachment cores, which is attached to a preferential locator; (b) is an m-discrete PEG as the terminal construct on the linear portion, and “hidden”; (c or linear discrete PEG with a terminus group that can be either negatively or positively charged, or neutral; and any of the discrete PEG portions can be designed to be cleaved after entering the cell.

The present invention relates to an X-ray dense conjugate, the use of the conjugate for producing a diagnostic and therapeutic composition, a pharmaceutical and / or diagnostic composition, which comprises said conjugate, a method for the diagnostic and / or analytical treatment of biological material or a living being, and a method for the therapeutic treatment of a living being.

The invention discloses a fusion protein of a single-chain antibody of a human anti-complement C3d molecule and a complement inhibitor CD59. The antibody has excellent antigen binding activity. Biological distribution experiments prove that the fusion protein provided by the invention can be rapidly and highly aggregated at an arthritis part after entering a rheumatoid arthritis mouse model, and has an excellent anti-adhesion / anti-inflammation targeting inhibition effect. In treatment of MRL / lpr lupus erythematosus mice, the fusion protein provided by the invention can obviously improve the survival rate of the mice, and symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis, crescent / necrosis and the like of a treatment group are obviously improved, so that the fusion protein provided by the invention has an excellent application prospect in preparation of medicaments for treating autoimmune diseases.

Devices, systems, and methods for therapeutically treating tissue. The devices and methods are suitable for minimally invasive surgery or open surgical procedures. More particularly, methods and devices described herein permit accessing and / or treating areas of tissue with a therapeutic device.

A self-exploration assembly includes a base and a plurality of petals each shaped so that when the plurality of petals are coupled to the base in a first orientation, the plurality of petals together resemble an onion, and, when the plurality of petals are coupled to the base in a second orientation, the plurality of petals resemble a flower.

The invention relates to a manipulated professional antigen presenting cell (APC) having increased expression of a CD1 type II molecule, preferably at least a CD1d molecule, relative to a control non manipulated cell. The invention further relates to the use of PPARg modulators in the preparation of a pharmaceutical composition or kit for the treatment of a disease treatable by activation of CD1d restricted T-cells, e.g. in autoimmune diseases, allergies, post-transplant conditions or infectious diseases, or in the treatment of a neoplastic disease, e.g. skin cancer, hematological tumors, colorectal carcinoma, and therapeutic compositions and kits therefor. Furthermore, the invention relates to methods of manipulating professional APCs and kits therefor.

The invention discloses a single-chain antibody of a human anti-complement C3d molecule, and a fusion protein of the single-chain antibody and a complement inhibitor DAF. The antibody has excellent antigen binding activity. Biological distribution experiments prove that the fusion protein provided by the invention can be rapidly and highly aggregated at an arthritis part after entering a rheumatoid arthritis mouse model, and has an excellent anti-adhesion / anti-inflammation targeting inhibition effect. In treatment of MRL / lpr lupus erythematosus mice, the fusion protein provided by the invention can obviously improve the survival rate of the mice, and symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis, crescent / necrosis and the like of a treatment group are obviously improved, so that the fusion protein provided by the invention has an excellent application prospect in preparation of medicaments for treating autoimmune diseases.

The invention belongs to the field of preparation of composite micelle entrapped drugs, and particularly relates to a composite nano micelle for multi-mode treatment of nasopharyngeal carcinoma and apreparation method and application thereof. The composite nano micelle for multi-mode treatment of nasopharyngeal carcinoma is characterized by comprising Bangladesh rose red and an amphiphilic peptide nano micelle for encapsulating the Bangladesh rose red. According to the invention, the amphiphilic peptide of C18-GRRRRRRRRGDScontaining a tripeptide sequence of arginine, glycine and aspartic is self-assembled into a nano micelle, and the inside of the nano micelle is wrapped with Bangladesh red; the results show that the a combined therapy group has obvious inhibitory effect on CNE-2Z tumor during intravenous injection. During intratumor injection, a photodynamic therapy group (RBNs+Laser) with laser added alone, a sonodynamic therapy group (RBNs+US) with ultrasound added alone and a combination therapy group (RBNs+Laser+US) all have a significant inhibitory effect on tumor growth.

The invention discloses a method for performing interceptive treatment on osteoarthritis of knee joints through dental pulp stem cells (DPSCs). The method comprises the following steps: injecting CFA(Complete Freund's Adjuvant) and MIA (Sodium Iodoacetate) through an articular cavity and performing induction for one week to obtain a rat model of the osteoarthritis of the knee joints; performing intervention and treatment on different groups of rats after one week, wherein a treatment group adopts interceptive treatment in a way of DPSCs cell suspension liquid articular cavity orthotopic injection or intravenous injection; taking materials after treatment for 4 weeks and analyzing a treatment effect, and evaluating the treatment effect of DPSCs on the osteoarthritis of the knee joints. According to the method disclosed by the invention, an experimental result proves that the DPSCs has a treatment effect on bone osteoarthritis induced by combination of CFA and MIA; after treatment for 4weeks, through DPSCs systematic or local injection, a knee joint bone structure induced by the combination of CFA and MIA can be recovered, and exudates of the articular cavity are reduced. Through the DPSCs systematic or local injection, a transparent cartilage arrangement structure and cell forms can be recovered.

A Self Monitoring And Reporting Therapeutics SMART® composition, method, apparatus and system are provided which flexibly provide options, by combining different embodiments of the device with different embodiments of the composition, the ability to conduct definitive medication adherence monitoring over the short term (Acute Medication Adherence Monitoring, immediately up to an hour or so after taking a medication), intermediate term (Intermediate Medication Adherence Monitoring, IMAM, an hour or so to a day or so after taking a medication), and longer term (Chronic Medication Adherence Monitoring, CMAM, a day to several days after taking a medication).

A method and system for performing a clinical trial having a reduced placebo effect is disclosed. The method includes randomizing study participants into three or more treatment groups and performing a first phase of testing on the groups. In a typical embodiment, the first phase of testing includes administering an active treatment to a first group, and administering a placebo to a second group and to a third group. Responders and non-responders are determined for each group. A second phase of testing is then performed. The second phase of testing includes administering the placebo to non-responders in the first group, administering the active treatment to non-responders in the second group, and administering the placebo to non-responders in the third group. The data from the first phase of testing and from the second phase of testing is pooled and analyzed to determine response rates to active treatment and placebo.

The invention specifically discloses an application of MSC for inhibiting virus replication, especially an application of MSC for inhibiting virus replication of a viral infection patient, and relatesto the technical field of biomedical engineering. According to the invention, a prepared MSC preparation is added into an MSC treatment group to carry out combined treatment on the viral infection patient, so that ribosomal gene expression of the patient can be recovered to the level of health personnel after the MSC treatment group is healed, and virus replication can be effectively inhibited after the MSC treatment group is healed.

The present disclosure provides methods of conducting and analyzing mouse clinical trials. In one embodiment, the method comprises the steps of receiving a dataset of tumor volumes measured in a mouse clinical trial, determining tumor growth curve of the treatment group and tumor growth curve of the control group; determining area under curve (AUC) of the treatment group and AUC of the control group; and evaluating efficacy of the drug based on an AUC ratio between the AUC of the treatment group and the AUC of the control group, wherein the mouse clinical trial comprises the steps of: obtaining a tumor sample derived from a patient; grafting the tumor sample to a treatment group comprising m mice and a control group comprising n mice, wherein m and n are integers; treating the treatment group with a drug; treating the control group with a vehicle; and measuring tumor volume of the treatment group and tumor volume of the control group at a plurality of days.

The invention belongs to the technical field of cells and discloses novel adult stem cells, a method for screening the same, a kit and application thereof. Biopsy samples, in vitro tissue samples, and cell line samples of normal tissues and tumors, precancerous tissues and tumors, carcinogenic tissues and metastatic tumors or cancer tissues of rodent, human or other mammals are screened by using chemotherapeutics and cell markers which are combined so as to obtain the stem cell groups. Moreover, the invention also discloses a method for screening and identifying the stem cells from the mixed cell groups, and the kit; and the method and the kit have the advantages of strong specificity, simplicity, convenience, quickness, practicality and effectiveness. The novel stem cells, the method for screening the same and the kit can be applied to clinic treatment, basis and application research, treatment, tissue engineering, medicine screening, and repairing and regeneration of diseased tissues and organs which loose functions well, and have wide prospect.